T. Rowe Price (VERA) reports 4.57M shares, 6.4% ownership (Amendment)

Rhea-AI Filing Summary

T. Rowe Price Associates, Inc. filed an Amendment No. 3 to Schedule 13G/A reporting beneficial ownership of 4,573,684 shares of Vera Therapeutics Inc. common stock, representing 6.4% of the class. The filing shows sole voting power of 4,570,810 shares and sole dispositive power of 4,573,684 shares. The filing is signed May 15, 2026, and includes a statement denying that T. Rowe Price is the beneficial owner of the securities.

Insights

Institutional Ownership Analyst

Amendment updates a 6.4% stake disclosure and voting/dispositive counts.

The filing lists 4,573,684 shares and a 6.4% ownership figure, with sole voting power of 4,570,810 shares and sole dispositive power of the same 4,573,684 shares. These are precise registry numbers used for regulatory transparency.

Significant dependencies include the underlying share class and any changes after 05/15/2026. Subsequent amendments would update these counts if the position changes.

Corporate Governance Specialist

Filing includes an explicit denial of beneficial ownership while reporting voting/dispositive powers.

The text contains a declarative clause that the filing “shall not be construed as an admission” and that beneficial ownership is “expressly denied.” That language affects how the disclosed numbers should be interpreted in governance contexts.

Practical implications depend on the legal relationship between T. Rowe Price and the shares; the filing itself does not provide that relationship detail.

Key Figures

Shares beneficially owned: 4,573,684 shares Percent of class: 6.4% Sole voting power: 4,570,810 shares +2 more

5 metrics

Shares beneficially owned 4,573,684 shares Amount beneficially owned reported in Item 4

Percent of class 6.4% Percent of common stock reported in Item 4

Sole voting power 4,570,810 shares Number with sole power to vote reported in Item 4

Sole dispositive power 4,573,684 shares Number with sole power to dispose reported in Item 4

Filing signature date 05/15/2026 Signed by Ellen York, Vice President

Key Terms

Schedule 13G/A, beneficially owned, sole dispositive power

3 terms

Schedule 13G/A regulatory

"Amendment No. 3 to Schedule 13G/A reporting ownership"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficially owned regulatory

"Amount beneficially owned: 4573684 (Percent of class: 6.4%)"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole dispositive power regulatory

"Sole power to dispose or to direct the disposition of: 4573684"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 10:07 AM Learn about SEC filing dates

FAQ

What stake did T. Rowe Price report in VERA?

T. Rowe Price reported ownership of 4,573,684 shares, representing 6.4% of Vera Therapeutics Inc. common stock. The filing lists sole voting power of 4,570,810 shares and sole dispositive power of 4,573,684 shares.

When was the Schedule 13G/A amendment signed?

The amendment is signed on 05/15/2026 by Ellen York, Vice President. That signature date is the execution date shown on the filing and anchors the disclosed ownership counts.

Does T. Rowe Price claim beneficial ownership of these shares?

The filing contains a statement that the submission “shall not be construed as an admission” and that beneficial ownership is “expressly denied.” The denial appears verbatim in the amendment text.

What voting and dispositive powers were reported?

The filing reports sole voting power of 4,570,810 shares, shared voting power of 0, sole dispositive power of 4,573,684 shares, and shared dispositive power of 0.

What issuer details are included in the filing?

The amendment names the issuer as VERA THERAPEUTICS INC and lists the principal executive office at 2000 Sierra Point Parkway, Suite 1200, Brisbane, CA 94005 as shown in the filing.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

VERA THERAPEUTICS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

92337R101

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 92337R101

1

Names of Reporting Persons

T. Rowe Price Associates, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,570,810.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,573,684.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,573,684.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.4 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: VERA THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE, CA, 94005
Item 2.
(a)	Name of person filing: T. Rowe Price Associates, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 92337R101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 4573684
(b)	Percent of class: 6.4 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 4570810
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 4573684
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Associates, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	05/15/2026